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Irritable Bowel Syndrome
Katherine J. Stillman, BSN, RN
Otterbein University, Westerville, Ohio
Introduction
Irritable bowel syndrome (IBS) has been defined as a poorly understood, chronic
gastrointestinal (GI) disorder without clear physical or biochemical dysfunction,
relating symptoms to psychological causes. Recent evidence proposes new
understanding of the interaction between the gut and brain, with a focus on the gut
microbiome and its role in the pathophysiology of the disorder (Ford et al., 2017).
IBS is a common condition presenting with persistent abdominal pain, altered bowel
habits and often bloating. Diagnosis is based upon the Rome IV criteria and use of the
Bristol stool form scale to categorize the appropriate IBS subtype: constipation,
diarrhea, or mixed symptoms of both (Ford et al., 2017).
My husband has struggled with the disorder since he was a child. I have seen firsthand how IBS can impact quality of life and the frustration with finding adequate
treatment. Commonly encountered in the primary care setting, the advanced practice
nurse will have an opportunity to provide care to these patients. Understanding the
current pathophysiology and diagnostic criteria can contribute to improved outcomes.
Epidemiologists estimate IBS affects nearly 11% of individuals throughout the
world. In the United States, it is as high as 20% (Canavan et al., 2014).
30% of those with IBS consult healthcare services (Canavan et al., 2014).
IBS is more common in women, sex hormones may play a role (Kim & Kim, 2018).
A recent nationwide prospective cohort study of >45,000 individuals in Sweden
suggests that IBS is not associated with increased mortality (Staller et al., 2020).
The impact of IBS on quality of life is significant and healthcare providers often
underestimate the burden on patients (Lacy, 2019).







Clinical Manifestations

Abdominal pain- cramping sensation with variable intensity and location. Pain is
often relieved with defecation. Stress and meals often affect pain intensity with
bloating and gas commonly experienced (Wald, 2019).
Altered bowel habits- includes diarrhea, constipation or a combination of both,
which can also alternate with normal bowel habits. The Bristol stool form scale is
used to identify stool consistency (Wald, 2019).
IBS subtypes
Based upon predominant bowel habit on days with abnormal bowel movements.





IBS-D (diarrhea)- frequent small volume loose stools. Often accompanied by
abdominal cramping and sensation of incomplete evacuation. 50% of patients
report mucus discharge. Type 6/7 Bristol stool scale.
IBS-C (constipation)- hard, pellet shaped stools often with sensation of
incomplete evacuation. Type 1/2 Bristol stool scale.
IBS-M (mixed)- combination of diarrhea and constipation
IBS-U (unclassified)- meets diagnostic criteria but unable to fit into one of the
three subtypes (Wald, 2019).

The Rome IV criteria serves as the national guideline for diagnosing IBS. In the
absence of warning signs such as unintentional weight loss, recent change in bowel
habits, positive fecal occult blood, overt GI bleeding or iron deficiency anemia, a
positive diagnosis can be made without subjecting the patient to unnecessary tests
(Ford et al., 2017).

Rome IV diagnostic criteria

(Heidelbaugh, 2017)

Bristol stool form scale
(Blake et al., 2016)

Pathophysiology

Gut Microbiome
Normal gut microbiota within the human
intestine is complex, involving thousands of
microbial species working together to maintain
homeostasis and protect against pathogens.
While in a constant state of change throughout
the lifespan, environment, diet and stress can
affect this balance. Recent studies suggest
changes in the gut microbiome play a key role in
IBS development (Chong et al., 2019).

Post infection: IBS is four times higher in those
who have had acute gastroenteritis in the last
year. Infection severity and female sex further
increase the risk (Pimentel & Lembo, 2020).
Bacterial toxins following gastroenteritis lead
to autoimmunity to vinculin, an intracellular
protein responsible for neuronal cell motility and
contractility in the GI tract (Pimentel & Lembo,
2020).
Dysbiosis: An imbalance of the microbial flora
creates dysbiosis. This alteration affects gut
integrity and modulation of the gut
neuromuscular junction (Chong et al., 2019).
In glucose or lactose breath testing, small
intestinal bacterial overgrowth is associated with
IBS-D (Pimentel & Lembo, 2020).
Antibiotic treatment with broad spectrum
antibiotics can contribute to dysbiosis leading to
the development of IBS (Hellström, 2019).
Stool transfer studies from ISB-D patients into
animals, elicits altered intestinal motility,
permeability and visceral hypersensitivity
(Pimentel & Lembo, 2020).
Excess colonization of Methanobrevibacter
smithii in the gut, produces elevated methane
gas leading to decreased intestinal motility and
constipation (Pimentel & Lembo, 2020).
Inflammation/immune activation: Low grade
intestinal mucosal inflammation can arise from a
compromised mucosal barrier, dysbiosis, post
infection and altered stress levels, stimulating
abnormal immune responses found in IBS
(Chong et al., 2019.)
Toll-like receptors are important mediators of
intestinal immune response to gut microbes.
Increased expression of intestinal Toll-like
receptors is associated with IBS (Pimentel &
Lembo, 2020).
Increased intestinal mucosal immune markers
such as intraepithelial lymphocytes, T cells and
mast cells are evident in patients with IBS. Mast
cells release substances that can sensitize
primary afferent neurons. Large numbers of
mast cells found close to nerves in the gut,
correlate with abdominal pain severity
(Hellström, 2019).

Illustrated summary of IBS pathophysiology
(Farmer, 2020)

IBS is a complex disorder and is
unlikely to be narrowed to down to
one cause as pathogenic factors that
produce symptoms vary among
individuals (Chong et al., 2019). This
functional disorder has long been
considered a dysregulation between

the brain and gut. Recent research
provides new understanding of this
relationship, with half of all cases
originating in the gut and
psychological symptoms following
(Ford et al., 2017).

Brain











Patients with IBS report more daily and lifetime stressful events as compared to healthy
individuals. The effects of stress on gut function is widespread, however those with IBS
tend to have greater responsiveness to stress (Hellström, 2019).
Emotional and physical stress can delay gastric emptying and intestinal transit,
disrupting the mucosal barrier causing the transmigration of bacteria leading to GI pain
and diarrhea (Drossman, 2016).
Psychological stress induces the secretion of pro-inflammatory cytokines that activate
the hypothalamic-pituitary-adrenal (HPA) axis triggering the release of stress hormones
that affect gut homeostasis (Chong et al., 2019).
Inflammatory cytokines are commonly found in patients with IBS and are highly
associated with anxiety and depression, suggesting the gut may have a role in regulating
brain function (Chong et al., 2019).
Two-way communication between the gut and brain occurs via the cingulate cortex and
peripheral GI tract. The perception of pain is influenced by this emotional mechanism,
allowing mental state to affect IBS symptoms (Lee et al., 2017). The cingulate cortex in
IBS patients is dysfunctional, in the presence of psychosocial distress, pain threshold is
decreased (Drossman, 2016).
Higher levels of anxiety and depression are experienced in patients with IBS regardless
of subtype (Lee et al., 2017).
Patterns of brain activation associated with anxiety may be associated with changes in
the microbiome of patients with IBS-D (Pimentel & Lembo, 2020).
While serotonin is usually associated with the brain, it is found mostly in the digestive
system and has an important role in GI motility. High levels of serotonin are associated
IBS-D and low levels with IBS-C (Chong et al., 2019).

Diet







The breakdown of food products plays a crucial role in the development of IBS by
affecting gut motility, the microbiome and visceral sensation (Chong et al., 2019).
Many patients report bloating and abdominal pain after ingestion of foods containing
fermentable oligosaccharides, disaccharides, monosaccharides and polyols
(FODMAPs). Methane production and osmotic effects may stimulate motility and
increase intraluminal fluid leading to bloating (Chong et al., 2019).
Gluten may alter intestinal permeability and activate the autonomous and enteric
nervous system leading to bloating and abdominal pain (Chong et al., 2019).
Research by Fritscher-Ravens et al. (2019) concludes that over 50% of patients with
IBS may have atypical food allergies, particularly to wheat. Utilizing confocal laser
endomicroscopy, disruption of the intestinal barrier with eosinophilic activation
occurred with exposure to food antigens, despite delayed clinical symptoms. Long
term follow-up found dramatically improved symptoms when food antigens were
removed from the diet.

Genetics

Visceral Hypersensitivity
Visceral hypersensitivity in IBS is the
perception of pain in the bowel in response
to normal GI movement. Abnormalities in
central pain processing, impaired mucosal
barrier, inflammation and alterations in gut
microbiome are possible contributors
(Chong et al., 2019).
Visceral hypersensitivity contributes to IBS
symptoms independent of anxiety and
depression comorbidity (Simren et al., 2016).







Concordance for IBS is greater among monozygotic twins.
Having a parent with IBS tends to be a greater predictor of
disease, but social learning may be a factor (Hellström, 2019).
Polymorphisms in genes responsible for serotonin signaling,
immune regulation and epithelial barrier function affecting
intestinal motility have been linked to IBS (Chong et al., 2019).
A mutation of a sodium channel gene SCN5A, associated with
abdominal pain, is the first mutation to be linked to IBS. In a
large genome-wide association study this mutation was present
in 2% of patients (Holtmann et al., 2016).

Significance of Pathophysiology

Recent research has uncovered exciting new evidence and understanding of IBS. While numerous and complex, these
perspectives are crucial to the development of effective treatments. Past management has focused on the most prevalent
symptoms, rather than on underlying pathophysiology and as a result the long-term course of the disorder is largely
unchanged (Holtmann et al., 2016).








No widely accepted treatment currently exists. Medications are only partially effective and with side effects. A multidisciplinary approach can provide the best outcomes in this complex disorder (Nelkowska, 2020).
GI symptoms may be the result of poor coping strategies. Short term psychological therapy is effective in reducing
abdominal symptoms with long term improvement (Nelkowska, 2020).
A low FODMAP diet can decrease abdominal pain, bloating and diarrhea by eliminating foods that produce bacterial
fermentation in the gut, however long-term use and follow-up is lacking (Pimentel & Lembo, 2020).
Many gastroenterologists believe diet to be an important part of IBS treatment, however only a small percentage
refer patients to dieticians (Nelkowska, 2020).
Rifaximin, a non-systemic antibiotic, has been recently approved by the Food and Drug Administration to treat
IBS-D. Reducing small intestinal bacteria is the likely mechanism of action (Pimentel & Lembo, 2020).
Probiotics have a role in reducing gut inflammation and improving barrier function. Effective strains are trial and
error. Future therapy will likely be based upon individual microbiota profiling (Chong et al., 2019).
Fecal transplantation is a current area of interest in improving the microbiome in IBS. It has not yet proven
successful given the challenge of finding the correct balance to normalize gut function (Hellström, 2019).

Nursing Implications

A pilot study conducted by Shannon Purdy (2017), utilized a crosssectional survey to examine the knowledge level of nurse practitioners (NPs)
within the primary care setting, concerning IBS pathophysiology, diagnosis,
and treatment. Overall, the survey found significant deficits in these areas
that did not correlate with experience level. While the study was small, it
provides valuable insight into the important role NPs have in understanding
the disorder and utilizing evidence-based care for the best outcomes.
NPs in the primary care setting can play a vital role in the collaborative
process of improving the lives of patients with IBS in the following ways:

Utilize the Rome IV diagnostic criteria to make a positive diagnosis and
avoid unnecessary tests or procedures.

Acknowledge that anxiety and depression are common co-morbidities.

Understand the current pathophysiology and new advances in the
treatment of the disorder (Weaver et al., 2017).

The following educational points can be beneficial in establishing a positive
relationship with IBS patients in the primary care setting:

IBS is a real disorder and not “in your head”.

IBS is a chronic condition with symptoms that can vary over time.

Quality of life can be significantly impacted with this disorder.

Stress can trigger or worsen symptoms.

There are many options to help manage symptoms, but no “magic pills”
to cure all the symptoms (Lacy, 2019).

Conclusion

IBS is a prevalent, chronic GI condition
associated with recurrent abdominal pain
and altered bowel habits. Although not
life- threatening, quality of life can be
significantly affected.
The pathophysiology involves a
complex interaction between the brain
and gut. Current knowledge has shifted
focus from a psychologically driven
etiology to an imbalance of the gut
microbiome. Future research will likely
involve the sequencing of the microbiome
in IBS patients, leading to individualized
treatment (Chong, et al., 2019).
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